Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena P Thomas

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
World Neurosurgery|August 28, 2020
Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for MelanomaMichael Zhang, Adrian J Rodrigues, Hriday P Bhambhvani, et al.
Academic Pediatrics|August 8, 2024
Underrepresented in Medicine Trainees' Sense of Belonging and Professional Identity Formation after Participation in the Leadership Education in Advancing Diversity ProgramLahia Yemane, Carmin Powell, Jeffrey Edwards, et al.
Cancer Reports (Hoboken, N.J.)|August 28, 2025
Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast CancerSeema Nagpal, Kim-Son Nguyen, Sophie Bertrand, et al.
Practical Radiation Oncology|July 28, 2022
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice GuidelineLia M Halasz, Albert Attia, Lisa Bradfield, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life ResultsErqi L Pollom, Dylann Fujimoto, Jacob Wynne, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Practical Radiation Oncology|February 3, 2023
Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant TemozolomideMaria G Mendoza, Melissa Azoulay, Steven D Chang, et al.
Neuro-Oncology|February 1, 2020
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomesMelissa Azoulay, Steven D Chang, Iris C Gibbs, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
World Neurosurgery|August 28, 2020
Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for MelanomaMichael Zhang, Adrian J Rodrigues, Hriday P Bhambhvani, et al.
Academic Pediatrics|August 8, 2024
Underrepresented in Medicine Trainees' Sense of Belonging and Professional Identity Formation after Participation in the Leadership Education in Advancing Diversity ProgramLahia Yemane, Carmin Powell, Jeffrey Edwards, et al.
Cancer Reports (Hoboken, N.J.)|August 28, 2025
Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast CancerSeema Nagpal, Kim-Son Nguyen, Sophie Bertrand, et al.
Practical Radiation Oncology|July 28, 2022
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice GuidelineLia M Halasz, Albert Attia, Lisa Bradfield, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life ResultsErqi L Pollom, Dylann Fujimoto, Jacob Wynne, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Practical Radiation Oncology|February 3, 2023
Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant TemozolomideMaria G Mendoza, Melissa Azoulay, Steven D Chang, et al.
Neuro-Oncology|February 1, 2020
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomesMelissa Azoulay, Steven D Chang, Iris C Gibbs, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pageof 2